Interleukin 6 (IL-6) is a potent cytokine, the
plasmacytoma cell proliferation assay. Supernatants from IL-1 stimulated synoviocytes from patients with rheumatoid arthritis (n=5) contained an average of 70 000 U/mI IL-6. Western blot analysis confirmed that these supernatants contained peptides that reacted with a highly specific antibody to IL-6. A cDNA probe specific for IL-6 hybridised with mRNA derived from synoviocytes representative of each disease state. Interleukin 6 mRNA expression increased by culturing synoviocytes in the presence of 10% calf serum, IL-1 (30 U/ml), insulin (166 ng/ml), or basic fibroblast growth factor (16 ng/ml). In contrast, dexamethasone mol/l) suppressed the ability of IL-1 to increase the expression of IL-6 mRNA. Recombinant IL-6 itself did not detectably upregulate its own message. The regulation of production of IL-6 by synoviocytes may be important in the pathogenesis of joint inflammation.
The pathogenesis of rheumatoid arthritis is poorly understood. Cytokines are thought to contribute to the process of inflammation. For example, interleukin 1 (IL-1) is detectable in joint fluid' and is produced by synoviocytes maintained in tissue culture.2 Furthermore, synoviocytes proliferate in response to IL-I.'
The biological properties of IL-I have suggested to many workers that it is an important contributor to inflammatory joint disease. 4 These properties include the ability to stimulate lymphocytes, act as a chemoattractant, induce prostaglandin synthesis, and stimulate the acute phase response. 5 Recent evidence indicates that many of the biological properties formerly ascribed to IL-1 may be mediated by IL-6.6 7 This peptide is also known as interferon 132, hepatocyte stimulating factor, B cell stimulatory factor 2, and hybridoma-plasmacytoma growth factor. 8 The rabbit antiserum was then detected by a goat-anti-rabbit IgG antibody conjugated to alkaline phosphatase (Tago). The same antiserum was also used to characterise the bioactivity detected in the B9 proliferation assay described above. Prestained molecular weight markers (Biorad) were run as size standards.
REAGENT
Recombinant human IL-la was the generous gift of Peter Lomedico (Hoffmann-LaRoche, Nutley, NJ, USA) Recombinant human IL-6 was purchased from R and D Systems. Basic fibroblast growth factor was a generous gift of Gary Shipley (Oregon Health Sciences University).
Results
To determine if synoviocytes were capable of secreting IL-6-like activity, supernatants from cultured synoviocytes from patients with rheumatoid arthritis, osteoarthritis, or trauma were tested for their ability to stimulate the proliferation of the IL-6 responsive B9 mouse plasmacytoma cell line. Figure 1 , a representative study, shows that supernatant from synoviocytes derived from a patient with traumatic joint disease did induce detectable mitogenesis in the B9 cell line. The To characterise further the IL-6 activity, we tested the ability of a polyclonal rabbit antiserum to IL-6 as an inhibitor of the mitogenic activity in supernatants from cultured synoviocytes. This antiserum markedly inhibited the ability of synoviocyte conditioned medium to stimulate B9 plasmacytoma cell proliferation. Figure 2 shows that supernatant from a synoviocyte culture derived from a patient with rheumatoid arthritis induced the proliferation of the B9 cell line. As was shown in fig 1, supernatant from synoviocytes cultured in the presence of IL-1 (30 U/ml) show an enhanced ability to stimulate mitogenesis of the B9 cell line. The antiserum to IL-6 at a dilution of either 1:50 or 1:100 inhibited the proliferative activity present in the supernatant from synoviocytes (fig 2) . The partial inhibition of proliferative activity in conditioned medium from IL-I stimulated synoviocytes indicates that the antiserum is not by itself toxic to plasmacytoma cells and is compatible with the concept that greater IL-6-like activity is detectable after IL-I stimulation.
To support further the hypothesis that supernatant from synoviocyte cultures contained IL-6, conditioned medium was tested for the presence of peptide reactive with antisera to IL-6 using Western blot analysis. Figure 3 shows that concentrated supernatant from synoviocytes cultured from a patient with rheumatoid arthritis, a patient with osteoarthritis, and a patient with traumatic joint disease contained peptides of approximate molecular weights of 19 000 to 24 000 which reacted with the antibody to IL-6. The IL-6-like peptides were detectable only after stimulation by IL-1. The potential of synoviocytes to synthesise IL-6 was studied further by Northern blot analysis. A 1-3 kb messenger RNA from primary synoviocyte cultures grown in the presence of 10% calf serum consistently hybridised to a cDNA probe specific for IL-6 (data not shown). Cultures from 12 different patients (three with rheumatoid arthritis, three with osteoarthritis, and six with trauma) were studied by Northern blot analysis for the presence of IL-6 mRNA. The transcript was detectable in all synovial cultures stimulated by serum. The induction of mRNA began within three hours of serum stimulation and lasted for at least 24 hours. Densitometry readings in representative studies indicated that the serum at least tripled the level of detectable mRNA specific for IL-6.
Consistent with the previous functional data and Western blot analysis, the IL-6 mRNA could be induced by culturing the cells with IL-1. Figure 4 shows that synoviocytes from a patient with rheumatoid arthritis, when cultured in the presence of IL-I for 48 hours, expressed a markedly increased level of IL-6 mRNA. In addition to the 13 kb transcript, further minor bands are detectable after IL-1 stimulation. These have been reported for other cell lines and may represent an IL-6 precursor, degradation products, or the effect of alternate mRNA splicing. To determine that the apparent difference in IL-6 expression in the presence of IL-I was not due to the unequal loading of lanes with amounts of mRNA, blots were re-probed with a cDNA for cyclophilin, a message which is constitutively expressed by a wide variety of tissues.24 These studies indicated that the enhanced detection of IL-6 mRNA could not be ascribed to the unequal loading of mRNA. In studies not shown here, the ability of IL-1 to induce mRNA was more marked at 48 hours than with culture for three or 18 hours.
Insulin (166 ng/ml) or basic fibroblast growth factor (16 ng/ml) also increased IL-6 mRNA expression approximately six fold. Figure 5 shows that the combination of insulin, fibroblast growth factor, and a small concentration of calf serum (0-33%) had a greater effect than any of these stimuli alone. In three separate studies (not shown), basic fibroblast growth factor by itself (16 ng/ml) increased the expression of IL-6 mRNA expression approximately three fold. Culturing synoviocytes in the presence of 2 < IL-6 (12-5 U/ml) failed to induce detectable I -expression of IL-6 mRNA ( fig 5) . 
